On the 22nd, at Hanmi Pharm headquarters, Kwon Se-chang, CEO of Hanmi Pharm (right), and Kim Jin-han, CEO of Standigm, shook hands after signing a joint research agreement.
[Asia Economy Reporter Choi Dae-yeol] Hanmi Pharmaceutical has decided to actively utilize artificial intelligence (AI) technology in the new drug development process.
On the 22nd, the company announced that it signed a joint research agreement with Standigm, an AI-based new drug development specialist company. Standigm is developing new drug candidate substances in various fields such as cancer and non-alcoholic fatty liver disease based on its proprietary AI technology, including the AI-based lead compound optimization platform Standigm Best.
In the early research stages of new drug development, a considerable amount of time and manpower is physically required, but it is expected that using AI technology will allow this process to be conducted more efficiently. According to this business agreement, the new drug candidate substances derived through cooperation between the two companies are expected to proceed to commercialization development, including clinical trials, production, and approval, under the leadership of Hanmi Pharmaceutical.
Kim Jin-han, CEO of Standigm, said, "We will focus our capabilities on commercializing new drug candidate substances discovered through AI in joint research with Hanmi Pharmaceutical." Kwon Se-chang, CEO of Hanmi Pharmaceutical, stated, "AI can play a significant role in drastically reducing time and costs in the early stages of new drug development and in deriving innovative candidate substances. Through this research collaboration, we will continuously derive promising candidate substances that can succeed in the global market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
